Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases. The ...

The world of drone technology has rapidly evolved in recent years, bringing cutting-edge innovation into the hands of hobbyists, professionals, and tech enthusiasts alike. Among the rising stars of ...

We all once believed that owning a drone is not something you do impulsively or without proper financial planning. It's either you go for a cheap fake drone or you go for an expensive high-quality ...

Peter earned a Bachelor of Archeology and Creative Writing from the University of Alabama and has since joined his love of driving and riding with storytelling. His voice is full of southern ...

Matt Nelson is an automotive journalist with nearly a decade of experience in all things cars. He's spent years working at dealerships in sales, finance, and service. He's since traded in his pens and ...

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Treatment with SKY-0515 also results in important dose-dependent ...

Skyhawk and Merck KGaA collaborate to discover RNA-targeting small molecules for neurological disorders using Skyhawk's SkySTAR platform. Skyhawk will focus on discovery and preclinical development, ...

Skyhawk Therapeutics enters into an option agreement to grant Merck exclusive global rights to drug candidates pursued under the collaboration upon option exercise Total deal value exceeds $2 billion ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be valued at more than $2 billion as the German company seeks to bolster its drug ...

BOSTON, Aug. 18, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Under the agreement, Skyhawk will use its RNA splicing platform, dubbed ...

Under the terms of the agreement, Skyhawk will use its proprietary SkySTAR ® (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to identify small molecule candidates ...